MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Moderna, Inc.

< Previous 1 2 3 4 5 Next >
Moderna Receives FDA Approval for Emergency Use Authorization of 2nd Booster Dose of Its COVID-19 Vaccine, mRNA-1273
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna Announces Clinical and Program Updates at 3rd Annual Vaccines Day
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna Finalizes Strategic Partnership with Australian Government
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna Announces its COVID-19 Vaccine Phase 2/3 Study in Children 6 Months to Under 6 Years Has Successfully Met Its Primary Endpoint
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna Announces New Supply Agreement for 2023 with Switzerland for Additional Seven Million Doses of Moderna's COVID-19 Booster Vaccine
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna Submits Amendment to the Emergency Use Authorization for an Additional Booster Dose of its COVID-19 Vaccine in the U.S.
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Health Canada Authorizes Moderna's COVID-19 Vaccine in Children (6-11 Years)
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna and the Japanese Government Reach an Agreement to Supply Japan with Additional 70 Million Doses of Moderna's COVID-19 Booster Vaccine
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna Announces First Participant Dosed in Phase 1 Study of its HIV Trimer mRNA Vaccine
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Bivalent Booster Candidate
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna to Host Third Annual Virtual Vaccines Day on March 24, 2022
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna Announces Its Global Public Health Strategy
From Moderna, Inc.
Via AccessWire
Topics Intellectual Property
Tickers MRNA
Moderna Announces Memorandum of Understanding with the Government of the Republic of Kenya to Establish its First mRNA Manufacturing Facility in Africa
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna Announces Establishment of Enterprise Solutions Hub in Atlanta, Georgia
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna to Present at Upcoming Conferences in March 2022
From Moderna, Inc.
Via AccessWire
Tickers MRNA
EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for The Use of The Moderna Covid-19 Vaccine in Children (6-11 Years) In the European Union
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Updates
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna Expands Global Footprint Through Commercial Partnership with Adium in Latin America
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna Initiates Phase 3 Portion of Pivotal Trial for mRNA Respiratory Syncytial Virus (RSV) Vaccine Candidate, Following Independent Safety Review of Interim Data
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna Expands Its mRNA Pipeline with Three New Development Programs
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Therapeutic Goods Administration of Australia Authorizes Moderna's Covid-19 Vaccine in Children (6-11 Years)
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna Announces Plan to Expand Commercial Footprint in Europe Across Six Additional Countries
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna and ROVI Expand Long-term Collaboration for the Manufacture of MRNA Medicines Over the Next Ten Years
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna Announces Plan to Expand Footprint in Asia with Four Additional Subsidiaries
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna Chief Technical Operations and Quality Officer Juan Andres Elected to National Academy of Engineering
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna Announces New Supply Agreement with Colombia for Additional 10.8 Million Doses of Moderna's COVID-19 Vaccine
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 24, 2022
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna Receives Full U.S. FDA Approval for COVID-19 Vaccine Spikevax
From Moderna, Inc.
Via AccessWire
Tickers MRNA
IAVI and Moderna Launch Trial of HIV Vaccine Antigens Delivered Through mRNA Technology
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Booster Candidate and Publication of Data on Booster Durability Against Omicron Variant
From Moderna, Inc.
Via AccessWire
Tickers MRNA
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
TOP
Email a Story